Pricing Panic vs. Franchise Reality: A Trade Idea on Novo Nordisk (NVO)
Novo Nordisk has been sold off aggressively after a wave of headlines about price cuts, mixed trial news and increased competition. The panic has pushed the stock to a $169B market cap and a PE of 10.8 while the business still controls scale advantages in GLP-1 manufacturing and a pipeline geared to oral formulations. This trade idea outlines a tac…